| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
18,500 |
17,020 |
$4.04M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
29,630 |
27,919 |
$3.51M |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
8,584 |
8,033 |
$1.40M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,097 |
4,524 |
$1.27M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,525 |
1,428 |
$889K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
6,574 |
6,249 |
$405K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
40,480 |
34,524 |
$300K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
9,144 |
8,347 |
$299K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
6,255 |
5,192 |
$298K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
15,645 |
12,913 |
$292K |
| 80053 |
Comprehensive metabolic panel |
33,913 |
29,224 |
$279K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
9,942 |
8,703 |
$252K |
| 71046 |
Radiologic examination, chest; 2 views |
5,365 |
5,006 |
$241K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
8,232 |
7,550 |
$224K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
5,664 |
5,116 |
$222K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,312 |
1,166 |
$188K |
| 71045 |
Radiologic examination, chest; single view |
2,984 |
2,727 |
$128K |
| J3490 |
Unclassified drugs |
75,564 |
30,188 |
$112K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,864 |
1,579 |
$105K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
1,723 |
1,031 |
$55K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,616 |
2,296 |
$46K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,080 |
2,741 |
$46K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,012 |
1,838 |
$39K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,824 |
1,770 |
$39K |
| 81025 |
|
4,576 |
4,120 |
$33K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
8,726 |
7,680 |
$33K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
3,727 |
3,401 |
$32K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,685 |
3,366 |
$31K |
| 84484 |
|
2,661 |
1,675 |
$30K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
276 |
233 |
$24K |
| 84703 |
|
2,367 |
2,174 |
$24K |
| 87430 |
|
1,483 |
1,436 |
$24K |
| G0378 |
Hospital observation service, per hour |
541 |
248 |
$23K |
| 83735 |
|
3,266 |
2,858 |
$21K |
| 81001 |
|
5,591 |
5,245 |
$18K |
| 82728 |
|
1,390 |
1,267 |
$18K |
| 83690 |
|
2,292 |
2,098 |
$17K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
293 |
265 |
$16K |
| 36591 |
|
1,302 |
790 |
$14K |
| 72020 |
|
466 |
357 |
$14K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
612 |
441 |
$14K |
| 87070 |
|
1,160 |
1,124 |
$14K |
| 59025 |
Fetal non-stress test |
230 |
210 |
$13K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
246 |
227 |
$13K |
| 80299 |
|
722 |
584 |
$13K |
| 83550 |
|
1,382 |
1,262 |
$11K |
| J7050 |
Infusion, normal saline solution, 250 cc |
3,352 |
1,562 |
$10K |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
12 |
12 |
$10K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
195 |
160 |
$9K |
| 83540 |
|
1,406 |
1,281 |
$8K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
128 |
81 |
$8K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
607 |
432 |
$8K |
| J9190 |
Injection, fluorouracil, 500 mg |
256 |
112 |
$6K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
13 |
12 |
$6K |
| 96367 |
|
191 |
126 |
$6K |
| 81003 |
|
2,299 |
2,160 |
$6K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
202 |
180 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
150 |
138 |
$5K |
| 80143 |
|
261 |
222 |
$5K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
67 |
56 |
$5K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
31 |
30 |
$5K |
| 82607 |
|
366 |
327 |
$5K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
293 |
291 |
$5K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
12 |
12 |
$4K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
266 |
230 |
$4K |
| 82746 |
|
333 |
295 |
$4K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
12 |
12 |
$4K |
| 88304 |
|
65 |
39 |
$4K |
| 96416 |
|
95 |
57 |
$4K |
| 36415 |
Collection of venous blood by venipuncture |
1,970 |
1,727 |
$4K |
| 80179 |
|
234 |
198 |
$4K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
164 |
159 |
$3K |
| J2704 |
Injection, propofol, 10 mg |
104 |
99 |
$3K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
218 |
180 |
$3K |
| J7999 |
Compounded drug, not otherwise classified |
316 |
222 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
140 |
128 |
$2K |
| 83605 |
|
175 |
147 |
$2K |
| 82533 |
|
220 |
164 |
$2K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
595 |
389 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
242 |
238 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
212 |
161 |
$1K |
| 96415 |
|
54 |
40 |
$1K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
302 |
237 |
$1K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
32 |
27 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
32 |
27 |
$1K |
| 76000 |
|
37 |
29 |
$1K |
| 73562 |
|
14 |
12 |
$1K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
29 |
28 |
$963.77 |
| 82550 |
|
141 |
112 |
$928.22 |
| 85610 |
|
262 |
215 |
$831.64 |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
16 |
12 |
$800.47 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
183 |
120 |
$765.98 |
| 96523 |
|
36 |
25 |
$742.50 |
| 83615 |
|
111 |
75 |
$707.78 |
| 84153 |
|
46 |
38 |
$691.27 |
| 84443 |
Thyroid stimulating hormone (TSH) |
84 |
65 |
$678.76 |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
24 |
24 |
$655.82 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
168 |
69 |
$632.29 |
| 84702 |
|
51 |
49 |
$545.00 |
| 94729 |
|
26 |
25 |
$472.10 |
| J8597 |
Antiemetic drug, oral, not otherwise specified |
1,134 |
964 |
$415.68 |
| 94727 |
|
14 |
13 |
$410.76 |
| 83880 |
|
15 |
12 |
$375.86 |
| 94060 |
|
14 |
13 |
$363.12 |
| J2060 |
Injection, lorazepam, 2 mg |
14 |
12 |
$336.27 |
| 82803 |
|
16 |
12 |
$300.73 |
| 85379 |
|
25 |
24 |
$298.16 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
13 |
12 |
$290.76 |
| 85730 |
|
48 |
44 |
$286.56 |
| 84439 |
|
53 |
39 |
$191.69 |
| 84550 |
|
45 |
25 |
$186.15 |
| 87420 |
|
14 |
13 |
$185.64 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
1,667 |
811 |
$183.13 |
| 87077 |
|
13 |
12 |
$171.60 |
| 85027 |
|
35 |
31 |
$163.59 |
| 87210 |
|
14 |
13 |
$100.75 |
| 84100 |
|
21 |
13 |
$88.30 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
39 |
12 |
$47.15 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
16 |
14 |
$0.49 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
14 |
13 |
$0.12 |